Effect of a fixed dorzolamide-timolol combination on intraocular pressure after small-incision cataract surgery with Viscoat.
OBJECTIVE
To evaluate the effect of a fixed dorzolamide-timolol combination (Cosopt) on intraocular pressure (IOP) after small-incision cataract surgery with sodium chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat).


METHODS
Department of Ophthalmology, University of Vienna, Vienna, Austria.


METHODS
This prospective randomized study comprised 76 eyes of 38 patients scheduled for small-incision cataract surgery in both eyes. Patients were randomized to receive 1 drop of the fixed dorzolamide-timolol combination in 1 eye or no treatment (control) immediately after cataract surgery. The fellow eye received the other assigned treatment. Cataract surgery was performed with Viscoat in an identical fashion in both eyes. The IOP was measured preoperatively and 6 hours, 20 to 24 hours, and 1 week postoperatively.


RESULTS
Six hours after surgery, the mean increase in IOP was significantly lower in the dorzolamide-timolol group than in the control group (4.3 mm Hg +/- 5.6 [SD] versus 8.4 +/- 6.1 mm Hg; P =.003). Two eyes in the dorzolamide-timolol group and 9 in the control group had IOP spikes of 30 mm Hg or higher (P =.022). Twenty to 24 hours after surgery, the mean IOP change was -2.6 +/- 3.3 mm Hg in the dorzolamide-timolol group and 1.5 +/- 3.2 mm Hg in the control group (P<.001).


CONCLUSIONS
The fixed dorzolamide-timolol combination was effective in reducing IOP 6 hours and 20 to 24 hours after cataract surgery. However, it did not prevent Viscoat-induced IOP spikes of 30 mm Hg or higher.
Rainer
Georg
G
Department of Ophthalmology, University of Vienna, Vienna, Austria. georg.rainer@akh-wien.ac.at
Menapace
Rupert
R
Findl
Oliver
O
Sacu
Stefan
S
Schmid
Katja
K
Petternel
Vanessa
V
Kiss
Barbara
B
Georgopoulos
Michael
M
D000368:Aged; D000369:Aged, 80 and over; D002387:Cataract Extraction / Q000379:methods; D002807:Chondroitin / Q000009:adverse effects / Q000627:therapeutic use*; D002809:Chondroitin Sulfates; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use*
D004338:Drug Combinations; D013449:Sulfonamides; D013876:Thiophenes; C501944:chondroitin sulfate, sodium hyaluronate drug combination; D013999:Timolol; D006820:Hyaluronic Acid; D002807:Chondroitin; D002809:Chondroitin Sulfates; C062765:dorzolamide